News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Staff Challenge Data On AstraZeneca PLC (AZN)'s Ovarian Cancer Drug Olaparib


6/24/2014 6:01:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - AstraZeneca Plc's experimental ovarian cancer drug, olaparib, showed an 83 percent reduction in the risk of disease progression, but a U.S. Food and Drug Administration staff review has questioned whether the result could be reproduced.

The company's shares fell 1.8 percent to 43.89 pounds on the London Stock Exchange.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters


comments powered by Disqus
Reuters
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES